Angiotensin-converting enzyme inhibition in myocardial infarction--Part 1: Clinical data.
Victor F. Huckell(University of British Columbia Hospital), A Wielgosz, S. Isserow, R C Orchard, Pierre Laramée, J. Wayne Warnica, Richard M. Prewitt, Fabio Maria Turazza, J A Cairns, Ping Liu(Shanghai University of Traditional Chinese Medicine), Gilles R. Dagenais(Institut universitaire de cardiologie et de pneumologie de Québec), Vr. K. Bernstein, B. Paul Quinn, Lyall Higginson(University of Ottawa), M Samson, Rebecca Crowell, John McCans
PubMed
February 1, 1997
Cited by 4
Related Papers
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
|The Lancet|2019|3.1k
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
|The Lancet Global Health|2019|1.2k
Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study
|The Lancet|2017|1.1k
Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries
|New England Journal of Medicine|2014|993